Cover Image
市場調查報告書

基質細胞衍生因子1:開發中產品分析

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 364868
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
基質細胞衍生因子1:開發中產品分析 Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 62 Pages
簡介

本報告提供以基質細胞衍生因子1為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

基質細胞衍生因子1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Juventas Therapeutics, Inc.
  • Momenta Pharmaceuticals, Inc.
  • Noxxon Pharma AG
  • TikoMed AB

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0976TDB

Summary:

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Stromal cell-derived factor 1 (SDF1) or C-X-C motif chemokine 12 (CXCL12) is a chemokine protein encoded by the CXCL12 gene. It activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. It binds to atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts as a scavenger receptor for SDF-1. It acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase. It stimulates migration of monocytes and T-lymphocytes through its receptors, CXCR4 and ACKR3, and decreases monocyte adherence to surfaces coated with ICAM-1.

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) pipeline Target constitutes close to 11 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Cardiovascular, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology and Other Diseases which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Angina (Angina Pectoris), B-Cell Chronic Lymphocytic Leukemia, Chronic Heart Failure, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Fecal Incontinence, Glioblastoma Multiforme (GBM), Metastatic Cancer, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, Myocardial Infarction, Neurology, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Transplant Rejection, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Primary Immune Deficiency (PID), Relapsed Multiple Myeloma, Solid Tumor, Spinal Cord Injury, Stroke, Trauma and Traumatic Brain Injury.

The latest report Stromal Cell Derived Factor 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12)
  • The report reviews Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Overview
    • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Companies Involved in Therapeutics Development
    • Cancer Research Technology Ltd
    • Cantex Pharmaceuticals Inc
    • Juventas Therapeutics Inc
    • Noxxon Pharma AG
    • TikoMed AB
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Drug Profiles
    • 1131-H12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 1143-H1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dociparstat sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Genistein - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IBsolvMIR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JVS-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • olaptesed pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CXCL12 for Primary Immune Deficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CXCL12 for Metastatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Target CXCR4 and SDF-1 for HIV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Dormant Products
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Discontinued Products
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 04, 2017: NOXXON Announces First Patients Treated in Phase I/II Clinical Trial of NOX-A12 Combined with Keytruda in Metastatic Pancreatic and Colorectal Cancer
      • Oct 10, 2016: NOXXON Pharma Demonstrates Synergies between NOX-A12 and Therapies Working Through T Cells or NK Cells
      • Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia
      • Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease
      • Jan 20, 2016: NOXXON Pharma Hosts Key Opinion Leader Symposium
      • Jun 16, 2015: Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy
      • Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01
      • May 26, 2015: Juventas Therapeutics Presents New 12-Month Data Demonstrating Single Administration of JVS-100 Improves Cardiac and Clinical Status in Patients with Severe Ischemic Heart Failure One Year After Treatment
      • May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting
      • Dec 05, 2014: Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference
      • Nov 18, 2014: Juventas Therapeutics Presents Phase II Data at AHA Scientific Sessions That Shows JVS-100 is Safe, Potentially Effective in Patients with Critical Limb Ischemia
      • Nov 12, 2014: Juventas Therapeutics Phase II Clinical Study Results to be Presented at 2014 American Heart Association Scientific Sessions
      • Sep 26, 2014: Cell Reports Publication on the Mechanism of Action of NOXXON's Anti-SDF-1 Spiegelmer Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models
      • Sep 25, 2014: Novel Compound Prevents Metastasis Of Multiple Myeloma In Mouse Studies
      • Sep 23, 2014: NOXXON Spiegelmer receives FDA Orphan Drug Designation for Glioblastoma Treatment
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Cancer Research Technology Ltd, H2 2017
  • Pipeline by Cantex Pharmaceuticals Inc, H2 2017
  • Pipeline by Juventas Therapeutics Inc, H2 2017
  • Pipeline by Noxxon Pharma AG, H2 2017
  • Pipeline by TikoMed AB, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top